{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:32:03Z","timestamp":1762507923777},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s11239-019-01989-5","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T11:03:44Z","timestamp":1572865424000},"page":"201-210","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Thromboembolism and bleeding risk in atrial fibrillation ablation with uninterrupted anticoagulation between new oral anticoagulants and vitamin K antagonists: insights from an updated meta-analysis"],"prefix":"10.1007","volume":"50","author":[{"given":"Xiao-Hua","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Fei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Feng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Zhou","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,4]]},"reference":[{"issue":"8","key":"1989_CR1","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","volume":"129","author":"SS Chugh","year":"2014","unstructured":"Chugh SS, Havmoeller R, Narayanan K et al (2014) Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 129(8):837\u2013847. \nhttps:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.005119","journal-title":"Circulation"},{"key":"1989_CR2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000665","author":"CT January","year":"2019","unstructured":"January CT, Wann LS, Calkins H et al (2019) 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation. Circulation. \nhttps:\/\/doi.org\/10.1161\/CIR.0000000000000665","journal-title":"Circulation"},{"issue":"25","key":"1989_CR3","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1161\/CIRCULATIONAHA.113.006426","volume":"129","author":"L Di Biase","year":"2014","unstructured":"Di Biase L, Burkhardt JD, Santangeli P et al (2014) Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation 129(25):2638\u20132644. \nhttps:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.006426","journal-title":"Circulation"},{"issue":"6","key":"1989_CR4","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.cjca.2015.09.012","volume":"32","author":"R Nairooz","year":"2016","unstructured":"Nairooz R, Ayoub K, Sardar P et al (2016) Uninterrupted new oral anticoagulants compared with uninterrupted vitamin K antagonists in ablation of atrial fibrillation: a meta-analysis. Can J Cardiol 32(6):814\u2013823. \nhttps:\/\/doi.org\/10.1016\/j.cjca.2015.09.012","journal-title":"Can J Cardiol"},{"issue":"1","key":"1989_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/europace\/eux275","volume":"20","author":"H Calkins","year":"2018","unstructured":"Calkins H, Hindricks G, Cappato R et al (2018) 2017 HRS\/EHRA\/ECAS\/APHRS\/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. Europace 20(1):157\u2013208. \nhttps:\/\/doi.org\/10.1093\/europace\/eux275","journal-title":"Europace"},{"key":"1989_CR6","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535. \nhttps:\/\/doi.org\/10.1136\/bmj.b2535","journal-title":"BMJ"},{"issue":"28","key":"1989_CR7","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1093\/eurheartj\/ehv177","volume":"36","author":"R Cappato","year":"2015","unstructured":"Cappato R, Marchlinski FE, Hohnloser SH et al (2015) Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J 36(28):1805\u20131811. \nhttps:\/\/doi.org\/10.1093\/eurheartj\/ehv177","journal-title":"Eur Heart J"},{"issue":"17","key":"1989_CR8","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1701005","volume":"376","author":"H Calkins","year":"2017","unstructured":"Calkins H, Willems S, Gerstenfeld EP et al (2017) Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. N Engl J Med 376(17):1627\u20131636. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1701005","journal-title":"N Engl J Med"},{"issue":"32","key":"1989_CR9","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1093\/eurheartj\/ehy176","volume":"39","author":"P Kirchhof","year":"2018","unstructured":"Kirchhof P, Haeusler KG, Blank B et al (2018) Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. Eur Heart J 39(32):2942\u20132955. \nhttps:\/\/doi.org\/10.1093\/eurheartj\/ehy176","journal-title":"Eur Heart J"},{"key":"1989_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz190","author":"SH Hohnloser","year":"2019","unstructured":"Hohnloser SH, Camm J, Cappato R et al (2019) Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. Eur Heart J. \nhttps:\/\/doi.org\/10.1093\/eurheartj\/ehz190","journal-title":"Eur Heart J"},{"issue":"1","key":"1989_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jjcc.2016.03.014","volume":"69","author":"A Yoshimura","year":"2017","unstructured":"Yoshimura A, Iriki Y, Ichiki H et al (2017) Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. J Cardiol 69(1):228\u2013235. \nhttps:\/\/doi.org\/10.1016\/j.jjcc.2016.03.014","journal-title":"J Cardiol"},{"issue":"5","key":"1989_CR12","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/jce.12928","volume":"27","author":"T Kuwahara","year":"2016","unstructured":"Kuwahara T, Abe M, Yamaki M et al (2016) Apixaban versus warfarin for the prevention of periprocedural cerebral thromboembolism in atrial fibrillation ablation: multicenter prospective randomized study. J Cardiovasc Electrophys 27(5):549\u2013554. \nhttps:\/\/doi.org\/10.1111\/jce.12928","journal-title":"J Cardiovasc Electrophys"},{"issue":"12","key":"1989_CR13","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jacep.2018.08.003","volume":"4","author":"T Kimura","year":"2018","unstructured":"Kimura T, Kashimura S, Nishiyama T et al (2018) Asymptomatic cerebral infarction during catheter ablation for atrial fibrillation: comparing uninterrupted rivaroxaban and warfarin (ASCERTAIN). JACC Clin Electrophysiol 4(12):1598\u20131609. \nhttps:\/\/doi.org\/10.1016\/j.jacep.2018.08.003","journal-title":"JACC Clin Electrophysiol"},{"issue":"6","key":"1989_CR14","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.hrthm.2015.02.028","volume":"12","author":"L Di Biase","year":"2015","unstructured":"Di Biase L, Lakkireddy D, Trivedi C et al (2015) Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: results from a multicenter study. Heart Rhythm 12(6):1162\u20131168. \nhttps:\/\/doi.org\/10.1016\/j.hrthm.2015.02.028","journal-title":"Heart Rhythm"},{"issue":"4","key":"1989_CR15","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1161\/CIRCEP.114.001586","volume":"7","author":"R Dillier","year":"2014","unstructured":"Dillier R, Ammar S, Hessling G et al (2014) Safety of continuous periprocedural rivaroxaban for patients undergoing left atrial catheter ablation procedures. Circ Arrhythm Electrophysiol 7(4):576\u2013582. \nhttps:\/\/doi.org\/10.1161\/CIRCEP.114.001586","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"1","key":"1989_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.amjcard.2014.10.005","volume":"115","author":"BM Kaess","year":"2015","unstructured":"Kaess BM, Ammar S, Reents T et al (2015) Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon. Am J Cardiol 115(1):47\u201351. \nhttps:\/\/doi.org\/10.1016\/j.amjcard.2014.10.005","journal-title":"Am J Cardiol"},{"issue":"4","key":"1989_CR17","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.amjcard.2017.11.015","volume":"121","author":"M Kottmaier","year":"2018","unstructured":"Kottmaier M, Bourier F, Pausch H et al (2018) Safety of uninterrupted periprocedural edoxaban versus phenprocoumon for patients who underwent left atrial catheter ablation procedures. Am J Cardiol 121(4):445\u2013449. \nhttps:\/\/doi.org\/10.1016\/j.amjcard.2017.11.015","journal-title":"Am J Cardiol"},{"issue":"10","key":"1989_CR18","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.jacc.2013.11.039","volume":"63","author":"D Lakkireddy","year":"2014","unstructured":"Lakkireddy D, Reddy YM, Di Biase L et al (2014) Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 63(10):982\u2013988. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2013.11.039","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1989_CR19","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/jce.12143","volume":"24","author":"W Maddox","year":"2013","unstructured":"Maddox W, Kay GN, Yamada T et al (2013) Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation. J Cardiovasc Electrophys 24(8):861\u2013865. \nhttps:\/\/doi.org\/10.1111\/jce.12143","journal-title":"J Cardiovasc Electrophys"},{"issue":"9","key":"1989_CR20","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.hrthm.2015.04.016","volume":"12","author":"T Nagao","year":"2015","unstructured":"Nagao T, Inden Y, Yanagisawa S et al (2015) Differences in activated clotting time among uninterrupted anticoagulants during the periprocedural period of atrial fibrillation ablation. Heart rhythm 12(9):1972\u20131978. \nhttps:\/\/doi.org\/10.1016\/j.hrthm.2015.04.016","journal-title":"Heart rhythm"},{"issue":"5","key":"1989_CR21","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.jacep.2017.11.005","volume":"4","author":"MR Reynolds","year":"2018","unstructured":"Reynolds MR, Allison JS, Natale A et al (2018) A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clin Electrophysiol 4(5):580\u2013588. \nhttps:\/\/doi.org\/10.1016\/j.jacep.2017.11.005","journal-title":"JACC Clin Electrophysiol"},{"key":"1989_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/pace.13370","author":"V Sawhney","year":"2018","unstructured":"Sawhney V, Shaukat M, Volkova E, Jones N, Providencia R, Honarbakhsh S, Dhillon G, Chow A, Lowe M, Lambiase PD, Dhinoja M, Sporton S, Earley MJ, Schilling RJ, Hunter RJ (2018) Catheter ablation for atrial fibrillation on uninterrupted direct oral anticoagulants: a safe approach. Pacing Clin Electrophysiol. \nhttps:\/\/doi.org\/10.1111\/pace.13370","journal-title":"Pacing Clin Electrophysiol"},{"issue":"3","key":"1989_CR23","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.amjcard.2017.04.041","volume":"120","author":"RR Shah","year":"2017","unstructured":"Shah RR, Pillai A, Schafer P et al (2017) Safety and efficacy of uninterrupted apixaban therapy versus warfarin during atrial fibrillation ablation. Am J Cardiol 120(3):404\u2013407. \nhttps:\/\/doi.org\/10.1016\/j.amjcard.2017.04.041","journal-title":"Am J Cardiol"},{"issue":"2","key":"1989_CR24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10840-016-0214-6","volume":"48","author":"S Tao","year":"2017","unstructured":"Tao S, Otomo K, Ono Y et al (2017) Efficacy and safety of uninterrupted rivaroxaban taken preoperatively for radiofrequency catheter ablation of atrial fibrillation compared to uninterrupted warfarin. J Interv Card Electrophysiol 48(2):167\u2013175. \nhttps:\/\/doi.org\/10.1007\/s10840-016-0214-6","journal-title":"J Interv Card Electrophysiol"},{"issue":"10","key":"1989_CR25","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/clc.22734","volume":"40","author":"K Vlachos","year":"2017","unstructured":"Vlachos K, Efremidis M, Bazoukis G et al (2017) Safety and efficacy of DOACs vs acenocoumarol in patients undergoing catheter ablation of atrial fibrillation. Clin Cardiol 40(10):847\u2013852. \nhttps:\/\/doi.org\/10.1002\/clc.22734","journal-title":"Clin Cardiol"},{"issue":"6","key":"1989_CR26","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1253\/circj.CJ-17-1114","volume":"82","author":"T Kojima","year":"2018","unstructured":"Kojima T, Fujiu K, Fukuma N et al (2018) Periprocedural complications in patients undergoing catheter ablation of atrial fibrillation without discontinuation of a vitamin K antagonist and direct oral anticoagulants. Circ J 82(6):1552\u20131557. \nhttps:\/\/doi.org\/10.1253\/circj.CJ-17-1114","journal-title":"Circ J"},{"issue":"1","key":"1989_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12872-018-0804-6","volume":"18","author":"M Brinkmeier-Theofanopoulou","year":"2018","unstructured":"Brinkmeier-Theofanopoulou M, Tzamalis P, Wehrkamp-Richter S et al (2018) Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants. BMC Cardiovasc Disord 18(1):71. \nhttps:\/\/doi.org\/10.1186\/s12872-018-0804-6","journal-title":"BMC Cardiovasc Disord"},{"key":"1989_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s10840-019-00563-6","author":"Y Osaka","year":"2019","unstructured":"Osaka Y, Ono Y, Tao S et al (2019) Feasibility and safety of uninterrupted apixaban in patients undergoing radiofrequency ablation for atrial fibrillation. J Interv Card Electrophysiol. \nhttps:\/\/doi.org\/10.1007\/s10840-019-00563-6","journal-title":"J Interv Card Electrophysiol"},{"issue":"3","key":"1989_CR29","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.hrthm.2017.10.033","volume":"15","author":"S Yanagisawa","year":"2018","unstructured":"Yanagisawa S, Inden Y, Fujii A et al (2018) Renal function and risk of stroke and bleeding in patients undergoing catheter ablation for atrial fibrillation: comparison between uninterrupted direct oral anticoagulants and warfarin administration. Heart Rhythm 15(3):348\u2013354. \nhttps:\/\/doi.org\/10.1016\/j.hrthm.2017.10.033","journal-title":"Heart Rhythm"},{"issue":"4","key":"1989_CR30","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692\u2013694. \nhttps:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x","journal-title":"J Thromb Haemost"},{"issue":"7","key":"1989_CR31","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1001\/jama.289.7.853","volume":"289","author":"AM Lincoff","year":"2003","unstructured":"Lincoff AM, Bittl JA, Harrington RA et al (2003) Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289(7):853\u2013863","journal-title":"JAMA"},{"issue":"23","key":"1989_CR32","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL et al (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123(23):2736\u20132747. \nhttps:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.009449","journal-title":"Circulation"},{"issue":"4","key":"1989_CR33","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/jce.12608","volume":"26","author":"T Deneke","year":"2015","unstructured":"Deneke T, Jais P, Scaglione M et al (2015) Silent cerebral events\/lesions related to atrial fibrillation ablation: a clinical review. J Cardiovasc Electrophys 26(4):455\u2013463. \nhttps:\/\/doi.org\/10.1111\/jce.12608","journal-title":"J Cardiovasc Electrophys"},{"issue":"13","key":"1989_CR34","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa022066","volume":"348","author":"SE Vermeer","year":"2003","unstructured":"Vermeer SE, Prins ND, den Heijer T et al (2003) Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 348(13):1215\u20131222. \nhttps:\/\/doi.org\/10.1056\/NEJMoa022066","journal-title":"N Engl J Med"},{"issue":"17","key":"1989_CR35","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1161\/CIRCULATIONAHA.110.937953","volume":"122","author":"F Gaita","year":"2010","unstructured":"Gaita F, Caponi D, Pianelli M et al (2010) Radiofrequency catheter ablation of atrial fibrillation: a cause of silent thromboembolism? Magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation. Circulation 122(17):1667\u20131673. \nhttps:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.937953","journal-title":"Circulation"},{"issue":"7","key":"1989_CR36","doi-asserted-by":"publisher","first-page":"e007197","DOI":"10.1161\/CIRCEP.119.007197","volume":"12","author":"M-N Jin","year":"2019","unstructured":"Jin M-N, Kim T-H, Kang K-W et al (2019) Atrial fibrillation catheter ablation improves 1-year follow-up cognitive function, especially in patients with impaired cognitive function. Circulation 12(7):e007197. \nhttps:\/\/doi.org\/10.1161\/CIRCEP.119.007197","journal-title":"Circulation"},{"issue":"5","key":"1989_CR37","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1161\/CIRCEP.113.000612","volume":"6","author":"A Verma","year":"2013","unstructured":"Verma A, Debruyne P, Nardi S et al (2013) Evaluation and reduction of asymptomatic cerebral embolism in ablation of atrial fibrillation, but high prevalence of chronic silent infarction: results of the evaluation of reduction of asymptomatic cerebral embolism trial. Circ Arrhythm Electrophysiol 6(5):835\u2013842. \nhttps:\/\/doi.org\/10.1161\/CIRCEP.113.000612","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"1","key":"1989_CR38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.hrthm.2018.07.011","volume":"16","author":"S Miyazaki","year":"2019","unstructured":"Miyazaki S, Kajiyama T, Yamao K et al (2019) Silent cerebral events\/lesions after second-generation cryoballoon ablation: how can we reduce the risk of silent strokes? Heart Rhythm 16(1):41\u201348. \nhttps:\/\/doi.org\/10.1016\/j.hrthm.2018.07.011","journal-title":"Heart Rhythm"},{"issue":"25","key":"1989_CR39","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1016\/j.jacc.2011.09.028","volume":"58","author":"R Cappato","year":"2011","unstructured":"Cappato R, Calkins H, Chen SA et al (2011) Delayed cardiac tamponade after radiofrequency catheter ablation of atrial fibrillation: a worldwide report. J Am Coll Cardiol 58(25):2696\u20132697. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2011.09.028","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1989_CR40","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R et al (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138(5):1093\u20131100. \nhttps:\/\/doi.org\/10.1378\/chest.10-0134","journal-title":"Chest"},{"issue":"23","key":"1989_CR41","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/j.jacc.2013.08.1623","volume":"62","author":"V Roldan","year":"2013","unstructured":"Roldan V, Marin F, Manzano-Fernandez S et al (2013) The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol 62(23):2199\u20132204. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2013.08.1623","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1989_CR42","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jacc.2019.04.061","volume":"74","author":"A Qamar","year":"2019","unstructured":"Qamar A, Antman EM, Ruff CT et al (2019) Edoxaban versus warfarin in patients with atrial fibrillation and history of liver disease. J Am Coll Cardiol 74(2):179\u2013189. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2019.04.061","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"1989_CR43","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1111\/jce.13314","volume":"28","author":"M Kottmaier","year":"2017","unstructured":"Kottmaier M, Bourier F, Semmler V et al (2017) Catheter ablation of left atrial arrhythmias on uninterrupted oral anticoagulation with vitamin K antagonists: What is the relationship between international normalized ratio, activated clotting time, and procedure-related complications? J Cardiovasc Electrophys 28(12):1415\u20131422. \nhttps:\/\/doi.org\/10.1111\/jce.13314","journal-title":"J Cardiovasc Electrophys"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-019-01989-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-019-01989-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-019-01989-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:14:21Z","timestamp":1604362461000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-019-01989-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,4]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["1989"],"URL":"https:\/\/doi.org\/10.1007\/s11239-019-01989-5","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,4]]},"assertion":[{"value":"4 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}